The Anatomy of Disaster
Act Sequence
Watch a Healthy Liver Become HCC
A healthy liver: rich mahogany parenchyma, portal vein bringing nutrient-rich blood from the gut (blue), hepatic artery oxygenating the tissue (red). Tap to watch it deteriorate.
Route
Cirrhosis → regenerative nodule → dysplastic nodule → HCC
Pattern
Arterial enhancement on triple-phase CT (arterial blush) + portal washout
Pearl
HBV causes HCC WITHOUT cirrhosis (unique among all risk factors)
Clinical Evidence
Real imaging and pathology. Tap to expand.
📷 CT ARTERIAL BLUSH · tap to expand
Triple-phase CT showing HCC
📷 GROSS PATHOLOGY · tap to expand
HCC in cirrhotic liver
The Tumor Marker
The Hit List
Ten things that beat up a liver until it gives in. Tap each card to see how it lands the hit.
Hepatitis B
DNA virus
tap →
Inserts viral DNA directly into hepatocyte genome. Chronic inflammation + direct oncogene activation. Causes HCC even without cirrhosis: the only major risk factor that does. HBV + aflatoxin = synergistic risk.
Hepatitis C
RNA virus
tap →
Drives chronic inflammation for 20+ years → cirrhosis → HCC. Most common HCC cause in the US. Almost always needs cirrhosis as the middle step. Surveillance: ultrasound q6mo + AFP.
Cirrhosis
Final common path
tap →
Scarred liver = constant cell turnover + repair. Every division is a mutation chance. Cirrhosis is the soil HCC grows from. Child-Pugh score determines treatment eligibility.
Aflatoxin
Aspergillus toxin
tap →
Aspergillus flavus on moldy peanuts and grain. Mutates the p53 tumor suppressor in hepatocytes. Synergistic with HBV. Classic stem: peanut farmer + HCC.
Alcohol
Chronic toxin
tap →
Ethanol → acetaldehyde damages DNA. Decades of inflammation → alcoholic cirrhosis → HCC. Works through the cirrhosis pathway, not directly onto hepatocyte DNA.
NASH
Metabolic syndrome
tap →
Non-alcoholic steatohepatitis: fat + inflammation → fibrosis → cirrhosis → HCC. Fastest-growing HCC cause worldwide as obesity rates rise. No alcohol required.
Wilson's Disease
Copper overload
tap →
ATP7B mutation → copper cannot leave the liver → oxidative damage → cirrhosis → HCC. Look for Kayser-Fleischer rings in the eye.
Hemochromatosis
Iron overload
tap →
HFE mutation → excess iron absorbed → deposits in liver → oxidative injury → cirrhosis → HCC. Classic: bronze skin, diabetes, arthritis.
Schistosomiasis
Parasitic worm
tap →
Freshwater fluke (Africa, Middle East). Eggs lodge in liver portal areas → granulomatous inflammation → fibrosis → HCC. Note: bladder schisto drives bladder SCC; liver schisto drives HCC.
Vinyl Chloride
NOT HCC
tap the trap →
Trap! Vinyl chloride hits the liver but grows angiosarcoma, not HCC. PVC factory exposure. AFP stays normal. Vinyl chloride = angiosarcoma. Every time.
Milan Criteria and Treatment
Each card is a treatment decision point. Flip to see what the criteria unlock.
Criterion 1
1 nodule ≤5 cm, no vascular invasion
Flip for treatment
Resection or transplant
Within Milan criteria. Best curative option. Transplant removes the cirrhotic liver too.
Criterion 2
Up to 3 nodules, each ≤3 cm
Flip for treatment
Resection or transplant
Also within Milan criteria. Multi-focal but still resectable / transplantable.
Bridge Therapy
Awaiting transplant list
Flip for treatment
TACE or ablation
Transarterial chemoembolization or radiofrequency ablation while waiting for a donor organ.
Advanced Disease
Outside Milan criteria, no metastasis
Flip for treatment
Sorafenib
Tyrosine kinase inhibitor (anti-VEGF, anti-RAF). First-line systemic for unresectable HCC.
Surveillance
Cirrhosis or chronic HBV
Flip for protocol
US + AFP q6 months
Ultrasound every 6 months plus AFP in cirrhotic patients. Triple-phase CT if nodule detected.
Budd-Chiari
Hepatic vein thrombosis
Flip for connection
HCC risk factor
Outflow obstruction → hepatic congestion → fibrosis → cirrhosis → HCC. RUQ pain + ascites + hepatomegaly triad.
Sort the Hits
Six patient clues. Eliminate the wrong cancer each round. Last one standing wins.
Which Liver Cancer?
Two cancers are in the ring. The clue tells you which one to KO. Tap the one that does NOT fit.
Round 1
Loading first clue...
Read the clue. Tap the cancer it does NOT fit.
Board Trap
Vinyl Chloride → Angiosarcoma
The most-tested distinction on the HCC risk list. Vinyl chloride absolutely damages the liver, but it grows a vascular tumor, not a hepatocyte tumor. Every other exposure (aflatoxin, alcohol, hepatitis, iron, copper) ends in HCC. If the stem says vinyl chloride or PVC factory, the answer is angiosarcoma. Period.
The One-Liner
Liver mass + AFP >400 = HCC.
Liver mass + vinyl chloride = angiosarcoma.
1 nodule ≤5 cm or 3 nodules ≤3 cm = Milan (resect/transplant). Beyond = sorafenib.
Liver mass + vinyl chloride = angiosarcoma.
1 nodule ≤5 cm or 3 nodules ≤3 cm = Milan (resect/transplant). Beyond = sorafenib.
Lock It In
Eight board-style stems. Pick your answer; the breakdown follows.
Q 1 of 8
A 54-year-old woman from West Africa presents with right upper quadrant fullness and 20-pound weight loss over 6 months. She grew up on a farm where stored grain frequently developed visible mold. Imaging shows a 5 cm hepatic mass. Serum AFP is 4,800 ng/mL. Which mechanism best explains her tumor?
B is correct. Mold on stored grain in a humid region is the setup for Aspergillus flavus producing aflatoxin. Aflatoxin slips into hepatocytes and mutates a specific codon on p53, removing the cell's brakes. AFP at 4,800 seals the diagnosis as HCC.
Why not the others? A is the vinyl chloride trap; that grows angiosarcoma, not HCC, and AFP stays normal in angiosarcoma. C (hemochromatosis) has no bronze skin or family history clue in this stem. D (HBV) would need an exposure history. Moldy grain story = aflatoxin every time.
Break it down: moldy peanuts or grain + liver mass + high AFP = aflatoxin HCC.
Why not the others? A is the vinyl chloride trap; that grows angiosarcoma, not HCC, and AFP stays normal in angiosarcoma. C (hemochromatosis) has no bronze skin or family history clue in this stem. D (HBV) would need an exposure history. Moldy grain story = aflatoxin every time.
Break it down: moldy peanuts or grain + liver mass + high AFP = aflatoxin HCC.
Q 2 of 8
A 67-year-old man worked 28 years as a polymerization operator at a PVC plastics plant. He now has abdominal distension and an ill-defined hepatic mass on CT. AFP is 6 ng/mL (normal). Biopsy shows pleomorphic malignant cells lining anastomosing vascular channels. What is the most likely diagnosis?
C is correct. PVC plant = vinyl chloride exposure. Vinyl chloride attacks the blood-vessel-lining cells (endothelium), not hepatocytes. Result: angiosarcoma. The biopsy clue "cells lining anastomosing vascular channels" is endothelial morphology. Normal AFP confirms it is not HCC.
Why not the others? A (HCC) is the classic trap. Same organ, completely different cell of origin. Vinyl chloride NEVER grows HCC. B (cholangiocarcinoma) arises in bile ducts, linked to PSC or liver flukes, not PVC. D (hepatic adenoma) is benign, linked to OCP use, and does not show malignant cells on biopsy.
Break it down: vinyl chloride + liver = angiosarcoma. AFP normal. Never HCC.
Why not the others? A (HCC) is the classic trap. Same organ, completely different cell of origin. Vinyl chloride NEVER grows HCC. B (cholangiocarcinoma) arises in bile ducts, linked to PSC or liver flukes, not PVC. D (hepatic adenoma) is benign, linked to OCP use, and does not show malignant cells on biopsy.
Break it down: vinyl chloride + liver = angiosarcoma. AFP normal. Never HCC.
Q 3 of 8
A 71-year-old man with 30-year heavy alcohol use and untreated hepatitis C presents for surveillance. CT shows a new 3 cm arterially enhancing nodule in a cirrhotic liver. Which lab finding would be most specific for HCC?
B is correct. AFP is the tumor marker for HCC. Fetal liver cells make it in utero; adults shut the gene off. Cancerous hepatocytes flip that fetal program back on. In a cirrhotic liver with a new arterially enhancing nodule, a markedly elevated AFP essentially diagnoses HCC without biopsy.
Why not the others? A (alk phos) rises in bile duct obstruction and bone disease; it is non-specific. C (CEA) is the colon cancer marker. D (CA 19-9) belongs to pancreatic and biliary tumors, including cholangiocarcinoma. Memorize the trio: AFP = HCC, CEA = colon, CA 19-9 = pancreas/biliary.
Break it down: AFP greater than 400 in a cirrhotic patient with a liver mass = HCC.
Why not the others? A (alk phos) rises in bile duct obstruction and bone disease; it is non-specific. C (CEA) is the colon cancer marker. D (CA 19-9) belongs to pancreatic and biliary tumors, including cholangiocarcinoma. Memorize the trio: AFP = HCC, CEA = colon, CA 19-9 = pancreas/biliary.
Break it down: AFP greater than 400 in a cirrhotic patient with a liver mass = HCC.
Q 4 of 8
A 58-year-old man with chronic HBV and no cirrhosis on biopsy develops a 4 cm hepatic mass. His AFP is 650 ng/mL. Which of the following best explains how HBV causes HCC without cirrhosis?
C is correct. HBV is a DNA virus that integrates its genome directly into hepatocyte chromosomes. This integration can disrupt tumor suppressor genes and activate proto-oncogenes. This is why HBV is the only major HCC risk factor that does NOT require cirrhosis as the intermediate step.
Why not the others? A describes hemochromatosis. B describes the usual cirrhosis pathway, which HBV can bypass via direct integration. D describes aflatoxin's mechanism. HBV's unique route is direct oncogene activation via chromosomal integration.
Break it down: HBV = direct DNA integration = HCC without cirrhosis. No other major risk factor does this.
Why not the others? A describes hemochromatosis. B describes the usual cirrhosis pathway, which HBV can bypass via direct integration. D describes aflatoxin's mechanism. HBV's unique route is direct oncogene activation via chromosomal integration.
Break it down: HBV = direct DNA integration = HCC without cirrhosis. No other major risk factor does this.
Q 5 of 8
A 60-year-old man with Child-Pugh A cirrhosis from hepatitis C has a single 4.5 cm HCC nodule on imaging with no vascular invasion and no metastases. Which treatment option offers the best chance of cure?
C is correct. This patient is within Milan criteria (single nodule 4.5 cm is under 5 cm, no vascular invasion). Liver transplantation both removes the tumor AND replaces the cirrhotic liver, eliminating the field defect. It offers the best long-term cure when criteria are met.
Why not the others? A (sorafenib) is for advanced, unresectable HCC outside Milan criteria. B (TACE) is palliative or a bridge to transplant, not curative monotherapy. D (cisplatin) has minimal efficacy in HCC. Within Milan criteria, resection or transplant is always the right answer.
Break it down: single nodule less than 5 cm = within Milan = transplant (best) or resection.
Why not the others? A (sorafenib) is for advanced, unresectable HCC outside Milan criteria. B (TACE) is palliative or a bridge to transplant, not curative monotherapy. D (cisplatin) has minimal efficacy in HCC. Within Milan criteria, resection or transplant is always the right answer.
Break it down: single nodule less than 5 cm = within Milan = transplant (best) or resection.
Q 6 of 8
A 45-year-old woman has genetic hemochromatosis with ferritin 3,400, bronze skin pigmentation, and biopsy-proven cirrhosis. What is her HCC risk and surveillance recommendation?
C is correct. Hemochromatosis with established cirrhosis carries significantly elevated HCC risk. Iron overload drives oxidative injury and DNA damage; cirrhosis provides the permissive soil. Surveillance protocol for ANY cirrhosis etiology: ultrasound plus AFP every 6 months. A negative AFP does not eliminate risk.
Why not the others? A is wrong; cirrhosis from any cause requires surveillance. B is backwards; surveillance is to find early disease, not to wait for AFP elevation. D (annual MRI) is not the standard surveillance interval or modality; ultrasound q6mo is.
Break it down: cirrhosis of any cause = ultrasound plus AFP every 6 months.
Why not the others? A is wrong; cirrhosis from any cause requires surveillance. B is backwards; surveillance is to find early disease, not to wait for AFP elevation. D (annual MRI) is not the standard surveillance interval or modality; ultrasound q6mo is.
Break it down: cirrhosis of any cause = ultrasound plus AFP every 6 months.
Q 7 of 8
A 52-year-old man presents with sudden-onset right upper quadrant pain, massive ascites, and tender hepatomegaly. CT shows no liver mass but evidence of hepatic vein thrombosis. Which of the following represents his long-term risk?
C is correct. This is Budd-Chiari syndrome: hepatic vein thrombosis causing outflow obstruction. Chronic congestion leads to hepatic fibrosis and eventually cirrhosis, which is the soil for HCC. The triad is RUQ pain + ascites + hepatomegaly.
Why not the others? A (cholangiocarcinoma) arises from bile duct injury, not venous outflow obstruction. B is incorrect; Budd-Chiari does increase HCC risk through its cirrhosis sequela. D is fabricated; portal hypertension does not cause splenic angiosarcoma.
Break it down: Budd-Chiari = hepatic vein thrombosis = congestion = fibrosis = cirrhosis = HCC risk.
Why not the others? A (cholangiocarcinoma) arises from bile duct injury, not venous outflow obstruction. B is incorrect; Budd-Chiari does increase HCC risk through its cirrhosis sequela. D is fabricated; portal hypertension does not cause splenic angiosarcoma.
Break it down: Budd-Chiari = hepatic vein thrombosis = congestion = fibrosis = cirrhosis = HCC risk.
Q 8 of 8
A 63-year-old man with cirrhosis from chronic alcohol use has an HCC that is too large for Milan criteria but has no extrahepatic metastases. His Child-Pugh score is B. Which treatment is indicated?
C is correct. This patient is outside Milan criteria (tumor too large) and Child-Pugh B (impaired liver function). He is not a transplant candidate without criteria downstaging, and resection requires adequate liver reserve (Child-Pugh A). For advanced HCC outside Milan criteria with preserved performance status, sorafenib is first-line systemic therapy.
Why not the others? A (transplant) requires meeting Milan criteria or successful downstaging. B (resection) requires Child-Pugh A liver function and adequate remnant. D (RFA) is curative only for small nodules, not large tumors outside criteria. Sorafenib extends survival in advanced HCC.
Break it down: outside Milan + unresectable = sorafenib. First-line systemic for advanced HCC.
Why not the others? A (transplant) requires meeting Milan criteria or successful downstaging. B (resection) requires Child-Pugh A liver function and adequate remnant. D (RFA) is curative only for small nodules, not large tumors outside criteria. Sorafenib extends survival in advanced HCC.
Break it down: outside Milan + unresectable = sorafenib. First-line systemic for advanced HCC.